Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
New drug for cardiovascular Diabetes grab: Giant lurking behind the rookie company
2014-08-04
来源：亚科官网
Since 2013 and the first half of 2014, there are a total of seven 1.1 class new drugs for cardiovascular disease, and 10 drugs related to type 2 diabetes treatment.
In the era of universal anti-tumor, it activated all the tumor-related biopharmaceutical companies. But the other two types of diseases following tumor have more than 110 million patients in the country—cardiovascular disease and diabetes.
The two are causal and have a strong family heredity. Therefore, the 1.1 categories of new drug statistics show that drugs associated with these two types of diseases are another fight territory following the tumor drugs,.
According to the statistics of the financial weekly, it can be seen that there were seven cases of cardiovascular drugs in 2013 and the first half of 2014, and there were 10 drugs related to the treatment of type 2 diabetes.
Interestingly, the companies that declare the two types of drugs are not imagined pharmaceutical giants, but are inextricably linked with some large pharmaceutical companies or capital side.
The industry and capital will try to find the iceberg hidden in the sea.
Hua Medicine—the first chariot
Two years ago, Hua Medicine launched an important project in Shanghai Zhangjiang Hi-Tech Park——Set up diabetes innovative drug project together with Roche Pharmaceutical, Roche China R&D Center, PharmaTech, Shanghai Ruijin Hospital.
August 15, 2013, class 1.1 anti-type 2 diabetes innovation drug HMS5552 from Hua Medicine obtained the State Food and Drug Administration clinical approval, and got the approval of clinical research institutions Fudan University Affiliated Zhongshan Hospital Ethics Committee on September 2, then started the clinical phase I study officially.
In fact, Hua Medicine is not the little known the entrepreneurial pharmaceutical companies, it is supported by Roche. Hua Pharmaceutical Technology (Shanghai) Co., Ltd. is a innovative pharmaceutical companies founded by Dr. Li Chen, the chief scientific officer of original Roche China R&D center. There also are 5 inventors of new drugs: Dr. Jack Baldwin, founder, president and chief executive officer of PharmaTech; Daniel Auerbach, executive director of Fidelity Asia Venture Capital; Robert Nelsen, executive director of ARCH Venture Capital, USA.
In addition, the Hua Medicine has also been favored by the capital side. Chen Lianyong, founder of Frontline BioVentures, has led the team to inject capital to Hua Medicine. Coincidentally, Chen Lianyong and Chen Li are the selection specialists of "The Recruitment Program of Global Experts".
A PE who invests in the field of medicine for a long-term introduce to the reporter of financial weekly newspaper (WeChat money-week), "The investors of Frontline BioVentures are Yuanhe mother fund, there are two funds of RMB and the dollar, the current total size is 200 million dollars. They focus on the field of life sciences, based on innovation, drug research and development, medical equipment. In addition to Hua Medicine, Frontline BioVentures also invested in CITIC medicine, Cathay Industrial Biotech, Haley biological and other biomedical enterprises. "
HMS5552 is a new generation of glucokinase activator, has a unique and innovative action mechanism, hoping to regulate blood sugar enhance through dual mechanism of the pancreatic glucose-stimulated insulin release and inhibition of liver endogenous glucose production, to control blood glucose changes in diabetics.
In addition to the drug, the Hua Medicine has also invested three global innovative drugs. The breakthrough from the first generic drug to the first innovation drug, it is the goal and ambition of whole team of Hua Medicine.
Chongqing Fuchon—the shadow of Fosun
Another new drug, DPP-4 inhibitors, for the treatment of type II diabetes is a competition project for many companies.
Money Weekly reporter learned in the survey, strictly speaking, the class of drugs can not be regarded as a real 1.1 new drugs.
The earliest declaration in domestic is in 2009, Hengrui launched Retagliptin. SuhaoSen declared Viglitin by 3+6 (API for the three categories, preparations for the six categories), Nanjing Warwick Pharmaceutical has been reported Viglitine/metformin compound by 3+3.
In 2013, a total of three pharmaceutical companies declared the DPP-4 inhibitors 1.1 new drugs, namely, Iglitine by Shandong Xuanzhu, Aeglitine by Shandong green leaves, Fotagliptin by Chongqing Fochon. Nevertheless, the domestic manufacturers are keen to DPP-4 inhibitors.
Among them, Chongqing Fochon has a powerful backing.
In fact, Chongqing Fochon Pharmaceutical Research Co., Ltd. is a small molecule innovative drug research and development center set up by Shanghai Fosun Pharmaceutical (Group) and overseas scientists team in 2009.
The announcement of the end of October 2013, Fosun Pharma agreed to hold Chongqing Fochon Pharmaceutical, and intended transfer Chongqing fochon and the relevant intellectual property and development, commercialization, sale and distribution, sublicense, external license and other applicable rights, title and interest of Fotagliptin Benzoate (benzoic acid complex lattice) and Pan -HER Inhibitors owned by its wholly owned subsidiary to "SELLAS", The price is 388 million euros. Affected by this news, then shares of Fosun Pharmaceutical is limit.
But to the beginning of July this year, things have a new trend. The announcement of Fosun Pharmaceutical on evening June 30 said that the transferee SELLAS should pay the transfer of 8 million euros, but the cumulative actual payment was 1.5 million euros. Chongqing Fochon decided to terminate the "transfer agreement". At that time, this money is not a one-time payment, is based on the progress of research and development to pay. Previously, it has been looking forward to bring more benefits through the drug development. We are afraid this dream has been shattered.
In fact, this transfer case has been questioned by the outside world at the very start, because the registered capital of SELLAS company is only 1.3 million RMB, mainly engaged in clinical research CRO, diagnostic reagents sales, medical equipment, etc. At the beginning, the reason why Fuxing won the praise, mainly start from the point of Chongqing Fochon's innovation ability, changing the situation of introduction drugs from abroad, but Fusun need to clean up the mess. "A medical fund manager analysis it to the reporter of financial weekly.
However, Chongqing Fochon is still an important chip for Fosun Pharma.
In the shareholders of Chongqing Fochon, Chongqing Medical Hospital, Shanghai Fosun New Drug Research Co., Ltd., Shanghai Wanbang and other Fosun series companies accounted for 70%, the remaining 30% was held by the team of scientists. It is worth mentioning that most of the scientists have overseas study background, most of the scientists have different years of drug research and development experience before returning. Fosun's capital is always interested in innovation. Fosun's road to expansion is a very typical way of capital expansion. It has formed a pharmaceutical circulation business, pharmaceutical business, medical services business, medical equipment and diagnostic.
Shandong Xuanzhu—Sihuan Medicine
Shandong Xuanzhu also declared DPP-4 inhibitors, but it also other applications, including calcium channel blockers Tylerdipine Hydrochloride for the treatment of hypertension. Of course, Shandong XuanZhu also has strong parent company behind to support.
Two years ago, Sihuan Pharmaceutical acquired the 17% and 23% equity of Shandong Xuanzhu Pharmaceutical, which was held by Huang Zhenhua and Cai Jun, respectively, through its indirect subsidiary, Hainan Sihuan, with a total consideration of RMB77.2 million.
In addition, Sihuan Pharmaceutical has acquired a 30% stake in Shandong Henry's ultimate holding company through its wholly-owned subsidiary, Yao Zhong International, at a consideration of $7.5 million. After the reorganization is completed, Shandong Xuanzhu Pharmaceutical will become a wholly-owned subsidiary of Sihuan Pharmaceutical.
As the Sihuan medicine has always invested on the R & D in the cardiovascular and cerebrovascular drugs, after the mergers and acquisitions are completed, Shandong XuanZhu continue to focus on cardiovascular drugs.
At present, the two new drugs are both declared by the Shandong XuanZhu, while the Sihuan medicine is resposible for overseas expansion.
In 2012, Sihuan Pharmaceutical entered into a cooperation agreement with NeuroVive Pharmaceutical AB, a leading global leader in mitochondrial technology development, listed on the Swedish Stock Exchange to develop two innovative drugs for the treatment of heart reperfusion injury and craniocerebral injury, respectively.
The original title: new drugs of cardiovascular diabetes: the Fosun and SiHuan behind the rookie companies
TAG: Chemical Reagents, Biomedicine
